BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35074700)

  • 21. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
    Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
    Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
    Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
    Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
    World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
    Dong W; Lei P; Liu X; Li Q; Cheng X
    Front Immunol; 2021; 12():686057. PubMed ID: 34804000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
    Okamoto I; Nakagawa K
    Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
    Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
    Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
    Schoppmann SF; Streubel B; Birner P
    Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina.
    Verzura M; Batagelj E; Bagnes C; Martin C; Enrico D; Richardet E; De la Iglesia P
    Ann Diagn Pathol; 2018 Jun; 34():77-81. PubMed ID: 29661733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidentally proven pulmonary "ALKoma".
    Osoegawa A; Nosaki K; Miyamoto H; Kometani T; Hirai F; Ondo K; Seto T; Sugio K; Choi YL; Soda M; Mano H; Ichinose Y
    Intern Med; 2010; 49(6):603-6. PubMed ID: 20228600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
    Wang B; Chen R; Wang C; Guo J; Yuan M; Chen H; Xia X; Zhong D
    Hum Pathol; 2021 Aug; 114():90-98. PubMed ID: 34019866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Driven Gene in Patients with Lung Squamous Cell Carcinoma: 
Analysis of Clinicopathologic Characteristics and Prognosis].
    Zhang T; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
    Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.